Background Although gemcitabine has been considered as the first-line drug for advanced
pancreatic cancer (PC), development of resistance to gemcitabine severely limits the …

Exosomes are a class of extracellular vesicles ranging in size from 40 to 100 nm, which are
secreted by both cancer cells and multiple stromal cells in the tumor microenvironment …

Background: Chemoresistance is a significant clinical problem in pancreatic cancer (PC)
and underlying molecular mechanisms still remain to be completely understood. Here we …

The triggering of gemcitabine (GEM) drug resistance in pancreatic cancer by the receptor for
advanced glycation end products (RAGE) has been demonstrated. Hence, finding a safe …

CircRNAs are a novel class of RNA molecules with a unique closed continuous loop
structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue …

Gemcitabine is a nucleoside analog that has been successfully used in the treatment of
multiple cancers. However, intrinsic or acquired resistance reduces the chemotherapeutic …

Chemoresistance including intrinsic and acquired anticancer drug resistance continues to
be a primary hindrance towards curative cancer treatment. Therefore, deciphering the …

RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and
therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant …

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …

Efficacy of chemotherapy in the treatment of distinct malignancies is often hampered by drug
resistance arising in the tumor. Understanding the molecular basis of drug resistance and …